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RAPID COMMUNICATION
Site specific regulation in the kidney of endothelin and its
receptor subtypes by cyclosporine
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Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Site selective regulation In the kidney of endothelin and its receptor
subtypes by cyclosporine. Endothelin (Et) has been suggested by us and
others to play a role in glomerular dysfunction that characterizes
cyclosporine (Cs)-associated nephrotoxicity. Since Et exerts its actions
through at least two receptor subtypes, and because these receptor
subtypes have particular distributions in the renal parenchyma, we
investigated changes in mRNA expression for Et and its receptor
subtypes in glomeruli and medulla of rats treated with Cs. Polymerase
chain reaction coupled with reverse transcription (RT-PCR) method
was used to assess prepro-Et-l, type A (EtA) and type B (EtB) receptor
mRNA at 1, 3, 6, and 24 hours after Cs (20 mg/kg body wt i.v.). Results
were normalized to the expression of -actin as an internal standard.
Compared with control rats, glomerular mRNA expression for prepro-
Et-1 was not affected by Cs. Similarly, Cs did not significantly change
the glomerular mRNA expression of either EtA or EtB receptor
subtypes. By contrast, in the medulla there was a marked and persistent
increase in the expression for prepro-Et-l and the EtB receptor
subtype: prepro-Et-! at 1, 3, 6, and 24 hours was 336 61, 295 65,
339 73,440 123%of controls, respectively (P <0.05 compared with
controls at each time point). The EtB receptor mRNA at 1, 3, 6, 24
hours was 164 22, 157 15, 148 14, 116 18% (compared with
controls, P < 0.01 at 3 hr and P < 0.05at 1 and 6 hr), while the rnRNA
expression for EtA was not affected by Cs treatment. These results
demonstrate that, in vivo, Cs selectively modulates renal mRNA
expression for Et peptide and one of its receptor subtypes. Further-
more, the modulation is site specific. These changes are most conspic-
uous in the renal medulla, such that mRNA expression for prepro-Et-l
and EtB increases and remains elevated for at least six hours after Cs
administration. These alterations may contribute to the vasospastic as
well as proliferative abnormalities which characterize Cs nephrotoxic-
ity.
Cyclosporine (Cs) has a well-recognized predilection to cause
renal dysfunction including glomerular hypoffitration as well as
cortical and medullary scarring, abnormalities that have re-
cently been linked to the actions of endothelin (Et). We and
others have shown that Cs stimulates Et production in both in
vivo and in vitro settings, increases Et binding in renal tissue
and increases urinary excretion of Et [1—5] . These findings
support persistent activation of Et gene and/or receptor regu-
lation within the kidney which contribute to Cs-associated
injury. Et and its receptor subtypes have been found throughout
the renal parenchyma. Thus, Et-1 has been localized within the
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medulla, especially inner medullary collecting duct [6, 71, while
cultured glomerular cells, including mesangial [8], endothelial
[9] and epithelial cells [10] all elaborate Et. Similarly, EtA and
EtB receptor subtypes have been localized within the glomer-
ulus [11] as well as the renal medulla [12].
To clarify the potentially distinct and separate modulation of
Et and its receptor subtypes by Cs, we studied expression for
Et, EtA and EtB in glomeruli and medulla of Cs treated rats
using polymerase chain reaction coupled with reverse transcrip-
tion (RT-PCR).
Methods
Materials
Random primer, ribonuclease H (RNAse H), dithiothreitol
(DTF) and SuperScriptTM reverse transcriptase with reaction
buffer (5x) (20 m Tris-HC1, 100 ms NaCl, 0.1 mr& EDTA, 1
ms DTT, 0.01% NP-40, and 50% glycerol) were purchased
from GIBCO/BRL (Gaithersburg, Maryland, USA). RNAsin
(RNAse inhibitor), Taq DNA polymerase with reaction buffer
(lOx) (50 mrvt Tris-HC1, 100 mt NaCI, 0.1 mt EDTA, 5 mti
DTT, 50% glycerol, and 1.0% Triton X-l00), deoxynucleotide
mixture (dNTP) and MgCI2 were purchased from Promega
Corporation (Madison, Wisconsin, USA).
Experimental protocols
Male Munich-Wistar rats weighing 200 to 220 g were used.
The animals had free access to water and standard rat chow
until the day of experiment. Each rat received Cs (Sandoz, East
Hanover, New Jersey, USA; 20 mg/kg body wt) through the tail
vein. Following pentobarbital sodium anesthesia (50 mg/kg
i.p.), both kidneys were harvested 1, 3, 6 or 24 hours after Cs
administration. Glomeruli were isolated by the sieving method.
Total RNA was extracted from isolated glomeruli from four
kidneys or medulla from one kidney; each of these constituted
a single experiment.
RNA extraction
Total RNA was prepared by acid-guanidinium-phenol-chlo-
roform (AGPC) method [13]. Briefly, tissue samples were lysed
by addition of 10 ml of RNA zol B® (TEL-TEST Inc., Friends-
wood, Texas, USA). Chloroform (1.0 ml) was added to lysates,
which was then vortexed vigorously for 30 seconds and iced for
15 minutes. After centrifugation at 12,000 g at 4°C for 30
minutes, RNA in an aqueous phase was precipitated with
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isopropanol for 30 minutes. Total RNA was pelleted by centrif-
ugation at 12,000 g at 4°C for 15 minutes, washed with 75%
ethanol and the resultant pellet dissolved in diethylpyrocarbon-
ate-treated H20. Samples were stored at —70°C.
Reverse transcription (RI')
Total RNA (2 g) from isolated glomeruli or renal medulla
was used in a RT reaction. The samples were heated to 70°C for
10 minutes, iced. Nineteen .Li of the RT reaction mixture
containing 50 ng random primer, 40 units RNAsin, 10 m DTT,
1 mM dNTP, 5x reaction buffer, and 200 units reverse tran-
scriptase were added. The reaction mixture was incubated at
37°C for 60 minutes. At the end of the incubation, the reaction
mixture was heated to 95°C for five minutes to inactivate the
reverse transcriptase activity and to denature RNA-cDNA
hybrids. The samples were treated with RNAseH at 37°C for 30
minutes. Two 1td of cDNA templates were used for each
polymerase chain reaction (PCR) reaction.
Polymerase chain reaction
PCR was performed with rat prepro-Et- 1, EtA and EtB
specific oligonucleotide primers prepared on a DNA synthe-
sizer (Applied Dept. of Molecular Physiology in Vanderbilt
University, Nashville, TN, USA). Prepro-Et-l primer 1 (anti-
sense) was defined by bases 341-360, sequence 5'-TGCTCCT-
GCTCCTCCTFGAT-3'; primer 2 (sense), bases 792-811, se-
quence 5'-CACCACGGGGCTCTGTAGTC-3' [14]. The eDNA
amplification product was predicted to be 471 bp in length. EtA
primer 1 (anti-sense) was defined by bases 538-557, sequence
5'-GAAGTCGTCCGTGGGCATCA-3'; primer 2 (sense), bases
734-753, sequence 5'-CTGTGCTGCTCGCCCTFGTA-3' [15].
The cDNA amplification product was predicted to be 216 bp in
length. EtB primer 1 (anti-sense) was defined by bases 1004-
1023, sequence S'-rI'ACAAGACAGCCAAAGACT-3'; primer
2 (sense), bases 1549-1568, sequence 5'-CACGATAGAGGA-
CAATGAAGAT-3' [16]. The PCR product was predicted to be
565 bp in length. Twenty-five picomoles of each of primers 1
and 2 were used per reaction for prepro-Et-1, EtA, EtB and
)3-actin. 5.0 U of Taq DNA polymerase were used in each PCR
reaction. The reaction mixture (100 j.d) was overlaid with 50 d
mineral oil. The tubes were placed in a Programmable Thermal
Controller, PTC-100 (MJ Research Inc., Watertown, Massa-
chusetts, USA) programmed as follows: incubation at 92°C for
three minutes (initial melt); then, (a) prepro Et-1: 35 cycles of
the following sequential steps: 92°C for 30 seconds (melt); 60°C
for 20 seconds (anneal); 72°C for one minute (extension); (b)
EtA, EtB and /3-actin: 27 cycles (EtA), 25 cycles (EtB) or 22
cycles (/3-actin) of the following sequential steps: 92°C for one
minute; 60°C for one minute; 72°C for one minute. Preliminary
experiments which determined the number of amplification
cycles for each mRNA species are shown in Figure 1. Final
incubation was performed at 72°C for five minutes. We per-
formed RT-PCR of f3-actin as an internal standard [17]. Beta-
actin primer 1 (anti-sense), bases 3055-3079, sequence 5'-
ACC'flCAACACCCCAGCCATGTACG-3'; primer 2 (sense),
bases 2170-2194, sequence 5'-CTGATCCACATCTGCTGGAA-
GGTGG-3'. Beta-actin primers spanned two introns and resulted
in a 703 bp product. PCR amplified products in 90 d of the total
reaction mixture were saved, and kept at —20°C until Southern
blot analysis.
Southern blot analysis of PCR products
The identity of PCR products was confirmed by Southern
hybridization. The PCR products were size-fractionated with
2% agarose gel electrophoresis and the DNA bands, visualized
with ethidium bromide staining, were photographed. PCR prod-
ucts were blotted to Gene Screen (DuPont New England
Nuclear, Boston, Massachusetts, USA) in 1OxSSC solution.
The blotted DNA was fixed by baking at 80°C for two hours.
Oligoprobes (antisense DNA) positioned between 5' and 3'
primers were synthesized to hybridize PCR products. The
sequence of each 20 oligonucleotide was 5'-CAAAGAACTC-
CGAGCCCAAA-3' (prepro-Et- 1), 5'-CCCCTFGAlTACCGC-
CATITG-3' (EtA), 5'-TGTGCTGCTGGTGCCAAACG-3' (EtB)
and 5'-CTGCGTCTGGACCTGGCTGGCCGGG-3' (/3-actin),
respectively [l4—17]. The synthetic oligonucleotide for hybrid-
ization was end-labeled with [y-32P] ATP (6,000 Cilmmol,
DuPont, New England Nuclear, Boston, Massachusetts, USA)
using a 5'-end oligonucleotide labeling kit (DuPont New En-
gland Nuclear Research Products). Prehybndization (3 hrs) and
hybridization (overnight) were carried out at 50°C (prepro-Et- I,
/3-actin) or at 65°C. After washing once (EtA, EtB) with 2xSSC,
0.5% SDS for 20 minutes, autoradiography was performed at
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Fig. 1. PCR ainpiffication curve of prepro-Et-
1, EtA and EtB receptor subtypes and /3-actin.
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Fig. 2. RT-PCR analysis of the time course for prepro-Et-1 and /3-actin as well as EtA and EtB receptor subtypes in glomeruli and medulla of
kidneys from control and Cs-treated rats. The upper panel of each set demonstrates the ethidium bromide stained PCR products in 2% agarose gel.
Arrows indicate the expected size for each PCR product. The lower panel shows the corresponding Southern blot probed with 32P-labeled
oligonucleotides that localized each PCR primer. In each set (glomeruli or medulla), lane 1 denotes control; lane 2 is 1 hr after Cs; lane 3 is 3 hr
after Cs; lane 4 is 6 hr alter Cs; lane 5 is 24 hr after Cs.
room temperature for 30 minutes, 50 minutes, 4 hours and
overnight for /3-actin, EtB, prepro-Et-l, and EtA, respectively.
Relative quantitation of mRNA level from autoradiographs
The optical density (OD) of mRNA for PCR products of
prepro-Et-1, EtA, EtB and /3-actin on the autoradiograph was
determined by Videodensitometry (Bio-Rad Laboratories,
Richmond, California, USA). Experimental OD value was
divided by the control OD value in each experiment and
expressed as a percent of control.
Statistics
Data are presented as mean SE. Wilcoxon signed rank test
was used to evaluate statistical significance. P < 0.05 was
considered to be significant.
Results
Figure 2 shows the ethidium bromide staining of agarose gels
and corresponding Southern blots for the PCR products for
prepro-Et-1, EtA, EtB and f3-actin mRNA in glomeruli and
medulla from kidneys of rats treated with Cs as well as controls.
The expected size of each PCR product is apparent: prepro-Et-l
(471 bp), EtA (216 bp), EtB (565 bp), and /3-actin (703 bp).
Southern hybridization using the specific oligoprobes confirmed
the identity of each of these PCR products. When PCR was
carried out in the absence of reverse transcriptase, these bands
were not seen, indicating that each band was derived from
mRNA, and not from the genomic DNA. The amplification
product of /3-actin served as an internal standard for the
RT-PCR reaction. The optimum number of amplification cycles
used for quantitative RT-PCR was chosen on the basis of pilot
experiments that established the linear range of the reaction
(Fig. 1).
Figures 3 and 4 graphically summarize the time course of
changes in mRNA expression for prepro-Et-l, EtA and EtB in
glomeruli and medulla from kidneys of Cs treated rats. Each
data point represents results from four to nine independent
experiments and is expressed as percent of the values obtained
in control rats. When compared with controls, glomerular
mRNA expression for prepro-Et-! was not significantly affected
by Cs. Thus, prepro-Et-1 at 1, 3, 6 and 24 hours was 77 20, 84
18, 60 18, and 84 21%, respectively (Fig. 3, open
triangles). By contrast, in the medulla, there were marked and
persistent increases in expression for prepro-Et-1 and the EtB
receptor subtype. Compared with controls, prepro-Et-1 mRNA
at 1, 3, 6 and 24 hours was 336 61, 295 65, 339 73, and
Medulla
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prepro-Et-1 and EtB was markedly and persistently increased.
* Previous studies showed that Cs stimulates Et production both
in in vivo and in vitro settings, and that the associated functional
changes such as glomerular hypoperfusion/hypofiltration or
cellular proliferation can be abrogated with Et antibody [1, 3, 5,
18]. These observations suggested that the Et peptide plays a
central role in Cs-related glomerular dysfunction, and that
antagonism of the peptide attenuates actions of Cs. The obser-
vations of the current study that glomerular prepro-Et-l mRNA
expression changes little following Cs suggests that the glomer-
ulus is not a primary source for enhanced Et production in this
setting. Instead, the current study demonstrates that the renal
medulla exhibits a striking and persistent increase in prepro-
Et-l mRNA expression. This suggests that vascular and/or
tubule epithelial cells in the medulla are important sites for
increased Et synthesis which in turn may induce glomerular
hemodynamic dysfunction as well as impact morphological
changes occurring in this region of the kidney chronically
exposed to Cs. This observation is in good agreement with
previous findings that epithelial cells, including the proximal
tubule-like LLC-PK1 cells [19, 20] and distal tubule-like MDCK
cells, are prolific producers of Et [21]. Further, the inner
medullary collecting duct cells (IMCD) contain the highest
___________________________________________
concentration of immunoreactive Et [22] and have been re-
cently shown to be the greatest producers of Et among tubule
cells [23, 24]. It should be noted that while the in vivo studies
emphasize the renal medulla as a primary current source of Et
production, higher doses of Cs, or more continuous exposure to
Cs (typical of in vitro experiments) may alter prepro-Et- 1
expression in glomerular cells.
In addition to effects on the Et peptide mRNA expression, Cs
also modulates the EtB receptor subtype. Thus, glomerular
receptor gene expression was not significantly affected by Cs in
the current study, whereas the renal medulla showed distinct
changes: mRNA expression for the EtB receptor subtype was
markedly and persistently above that seen in medulla of control
kidneys. As in the above discussion of prepro-Et-1, the en-
hanced medullary expression of EtB may reflect increases in
either vasa recta which express both receptor subtypes [11]
and/or in tubule epithelial cells. In this regard, IMCD cells have
been demonstrated to express either predominantly [12] or
exclusively EtB receptor subtype [11] and appear to bind more
Et than the other tubule cells [12]. Taken together, it appears
that previous observations of increased Et binding to medullary
tissue may reflect activity of the EtB receptor subtype. The
current findings are also in agreement with a preliminary study
in ischemic kidneys which found persistently increased mRNA
expression for Et and the EtB receptor subtype [25]. The
concurrent increase in the renal medullary mRNA expression
for both prepro-Et-1 and EtB receptor subtype raises the
intriguing possibility that Et may up-regulate one of its receptor
subtypes, at least in the renal medulla. Similar up-regulation of
Discussion a receptor by its ligand was recently described for the angio-
tensin system in rabbit proximal tubule cells where angiotensin
up-regulated the mRNA for the type 1 angiotensin receptor both
in in vitro and in vivo systems [26]. It is also possible that Cs
itself, independent of Et, directly modulates mRNA for both the
prepro-Et-l and EtB receptor subtype.
Lack of change in glomerular or medullary mRNA expression
for the EtA receptor subtype is of interest since previous
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Fig. 3. The time course for prepro-Et-l mRNA in glomeruli (——i—)
and medulla (—A—A—) of Cs-treated rats. Expression was analyzed by
using the RT-PCR method. '2P-labeled oligonucleotide probes for
prepro-Et-1 was hybridized with the PCR product and autoradiography
performed. Bands were quantified by densitometry. Each point was
normalized to the expression of /3-actin as internal standard. Values are
expressed as percent of control values. * Statistically significant differ-
ence versus control animals.
I I
440 123%, respectively; P < 0.05 compared to control at each
time point (Fig. 3, closed triangles). Cs did not change the
glomerular mRNA expression of either EtA or EtB receptor
subtypes; as shown in Figure 4A, glomerular mRNA expression
for EtA at 1,3,6 and 24 hours was 110 12, 106 14, 141
24, and 116 12%, respectively. Glomerular mRNA expression
for EtB at 1, 3, 6, 24 hours was 101.1 9.6, 119.0 10.3, 87.5
16.3, and 92.3 19.1% of the corresponding control values
(Fig. 4A). Medullary mRNA expression for the EtB receptor
subtype at 1, 3, 6 and 24 hours was 164 22, 157 15, 148
14, and 116 18%; P < 0.01 at 3 hours, P < 0.05 at I and 6
hours (Fig. 4B). The mRNA expression for EtA in the medulla
was only not significantly different from control values: EtA at
1, 3, 6 and 24 hours was 118 11, 119 13, 112 18, and 129
20%, respectively (Fig. 4B).
These studies show that Cs exerts a unique and distinct
modulation on the individual components of the endothelin
system, namely, the Et peptide and its receptor subtypes. In
addition, this modulation is site specific. Thus, glomeruli iso-
lated from kidneys of rats treated with Cs showed little changes
in the mRNA expression for prepro-Et-1, EtA or EtB over the
time period studied, while in the medulla, the expression of
A Glomeruli B Medulla
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Fig. 4. A. The time course for mRNA for
EtA (———) and EtB (—A—A—) receptor
subtypes in glomeruli from Cs-treated rats.
B. The time course of mRNA for EtA and
EtB receptor subtypes in the renal medulla of
the same rats. Expression was analyzed by
using the RT-PCR method. 32P-labeled
oligonucleotide probes for rat EtA and EtB
receptors were hybridized with each PCR
product and autoradiography performed.
Bands were quantified by a densitometer.
Each point was normalized to the expression
of fJ-actin as internal standard. Values are
expressed as percent of control values.
* Statistically significant difference versus
control animals.
studies have shown that EtA receptor antagonist can ameliorate
glomenilar hypofiltration associated with acute Cs administra-
tion and lessen the increase in myosin light chain phosphoryla-
tion in cultured mesangial cells exposed to Cs [18, 27]. More-
over, it has been demonstrated that Et binding to glomerular
membranes is increased in kidneys of animals given Cs [2].
These findings together with the present observations suggest
that Et exerts its actions through the EtA receptor in the
absence of discernible changes in the mRNA level of this
receptor subtype. Of great interest in this regard are the recent
observations that the endothelin-receptor complex is rapidly
internalized [28], followed by a slow reappearance of the
receptor sites [29, 30]. In one study [29], an EtA receptor
antagonist, BQ-123, attenuated Et-l induced contraction in
cardiac myocytes either before or after addition of endothelin.
These authors believe that efficacy of the receptOr antagonist
even after addition of the ligand suggests appearance of new
receptors and propose functional coupling of the recycling EtA
receptors. These findings support the notion that EtA-mediated
functions, such as contraction may not require up-regulation of
the receptor mRNA expression, instead, recycling of internal-
ized receptors (EtA) contribute to the powerful, long-lasting
effects of Et. Therefore, the increased Et binding to glomerular
membrane occurring in the absence of increased EtA receptor
mRNA expression may be the result of stimulated externaliza-
tion of these Et receptors.
In summary, the present study shows that administration of
Cs modulates renal mRNA expression for prepro-Et- I and the
EtB receptor subtype and demonstrates that the modulation is
site selective within the kidney. The renal medulla appears most
susceptible to Cs-induced changes in gene expression, such that
mRNA for prepro-Et- 1 and EtB remains persistantly elevated
after Cs administration. We hypothesize that, through paracrine
mechanisms, Et contributes to Cs-associated vasospasm, while
autocrine mechanisms are involved in the scarring which often
affects the renal medulla of Cs-exposed kidney.
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